---
title: Immune checkpoint inhibitors in non-small cell lung cancer - When should we
  dare to stop treatment?
date: '2023-09-01'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37657237/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230902181534&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: Over the last years, the emergence of immune checkpoint inhibitors (ICI)
  has revolutionized the treatment of non-small cell lung cancer (NSCLC). Patients
  in a palliative setting with previously very poor prognosis may now show remarkable
  responses over years. Yet, ICI therapy is very cost-intensive and involves frequent
  contacts with healthcare resources. Some of the early trial protocols restricted
  ICI treatment duration to two years. Now follow-up data of these studies is available
  and ...
disable_comments: true
---
Over the last years, the emergence of immune checkpoint inhibitors (ICI) has revolutionized the treatment of non-small cell lung cancer (NSCLC). Patients in a palliative setting with previously very poor prognosis may now show remarkable responses over years. Yet, ICI therapy is very cost-intensive and involves frequent contacts with healthcare resources. Some of the early trial protocols restricted ICI treatment duration to two years. Now follow-up data of these studies is available and ...